Deferred Tax Assets, Valuation Allowance of GT Biopharma, Inc. from 31 Dec 2011 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
GT Biopharma, Inc. quarterly Deferred Tax Assets, Valuation Allowance in USD history and change rate from 31 Dec 2011 to 31 Dec 2025.
  • GT Biopharma, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending 31 Dec 2025 was $141,106,000, a 26% increase year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Change (%)

GT Biopharma, Inc. Quarterly Deferred Tax Assets, Valuation Allowance (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $141,106,000 +$28,922,000 +26% 31 Dec 2025 10-K 02 Mar 2026 2025 FY
Q4 2024 $112,184,000 +$2,492,000 +2.3% 31 Dec 2024 10-K 02 Mar 2026 2025 FY
Q4 2023 $109,692,000 -$3,295,000 -2.9% 31 Dec 2023 10-K 21 Feb 2025 2024 FY
Q4 2022 $112,987,000 -$14,861,000 -12% 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q4 2021 $127,848,000 +$25,221,000 +25% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q4 2020 $102,627,000 +$6,054,000 +6.3% 31 Dec 2020 10-K 28 Mar 2022 2021 FY
Q4 2019 $96,573,000 +$9,346,000 +11% 31 Dec 2019 10-K 16 Apr 2021 2020 FY
Q4 2018 $87,227,000 +$71,284,000 +447% 31 Dec 2018 10-K 27 Mar 2020 2019 FY
Q4 2017 $15,943,000 -$5,499,000 -26% 31 Dec 2017 10-K 29 Mar 2019 2018 FY
Q4 2016 $21,442,000 +$5,027,000 +31% 31 Dec 2016 10-K 01 Mar 2018 2017 FY
Q4 2015 $16,415,000 +$1,078,000 +7% 31 Dec 2015 10-K/A 28 Feb 2018 2016 FY
Q4 2014 $15,337,000 +$29,758,000 31 Dec 2014 10-K/A 28 Feb 2018 2015 FY
Q4 2013 $14,421,000 -$396,218 -2.8% 31 Dec 2013 10-K 31 Mar 2015 2014 FY
Q4 2012 $14,024,782 -$1,137,782 -8.8% 31 Dec 2012 10-K 08 Jan 2015 2013 FY
Q4 2011 $12,887,000 31 Dec 2011 10-K 18 Nov 2014 2012 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.